Citations (40)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Vibeke Strand, Giampiero Girolomoni, Martin Schiestl, Robert Ernst Mayer, Hilke Friccius-Quecke & Mark McCamish. (2017) The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilar. Current Medical Research and Opinion 33:6, pages 993-1003.
Read now
Read now
Luciane Cruz Lopes, Miriam Sanches do Nascimento Silveira, Mayara Costa de Camargo, Iara Alves de Camargo, Tatiana Chama Borges Luz, Claudia Garcia Serpa Osorio-de-Castro, Silvio Barberato-Filho, Fernando de Sá Del Fiol & Gordon Guyatt. (2014) Patient reports of the frequency and severity of adverse reactions associated with biological agents prescribed for psoriasis in Brazil. Expert Opinion on Drug Safety 13:9, pages 1155-1163.
Read now
Read now
Giuseppe Murdaca, Francesca Spanò, Miriam Contatore, Andrea Guastalla, Ottavia Magnani & Francesco Puppo. (2014) Efficacy and safety of etanercept in chronic immune-mediated disease. Expert Opinion on Drug Safety 13:5, pages 649-661.
Read now
Read now
Articles from other publishers (37)
Daniela Anghel, Carmen Adella Sîrbu, Oana-Georgiana Petrache, Daniela Opriș-Belinski, Maria Magdalena Negru, Violeta-Claudia Bojincă, Cristina Florentina Pleșa & Florentina Ioniță Radu. (2023) Nailfold Videocapillaroscopy in Patients with Rheumatoid Arthritis and Psoriatic Arthropathy on ANTI-TNF-ALPHA Therapy. Diagnostics 13:12, pages 2079.
Crossref
Crossref
Proton Rahman, Wolf-Henning Boehncke, Philip J. Mease, Alice B. Gottlieb, Iain B. McInnes, May Shawi, Yanli Wang, Shihong Sheng, Alexa P. Kollmeier, Elke Theander, Jenny Yu, Evan Leibowitz, A. Marilise Marrache & Laura C. Coates. (2023) Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic Arthritis. The Journal of Rheumatology 50:6, pages 769-780.
Crossref
Crossref
Christopher T. Ritchlin, Atul Deodhar, Wolf‐Henning Boehncke, Enrique R. Soriano, Alexa P. Kollmeier, Xie L. Xu, Federico Zazzetti, May Shawi, Yusang Jiang, Shihong Sheng & Philip S. Helliwell. (2023)
Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized,
Placebo‐Controlled DISCOVER
‐1 Study
. ACR Open Rheumatology 5:3, pages 149-164.
Crossref
Crossref
Jingyi Hu, Qiong Bian, Xiaolu Ma, Yihua Xu & Jianqing Gao. (2022) A double-edged sword: ROS related therapies in the treatment of psoriasis. Asian Journal of Pharmaceutical Sciences 17:6, pages 798-816.
Crossref
Crossref
Proton Rahman, Christopher T. Ritchlin, Philip S. Helliwell, Wolf-Henning Boehncke, Philip J. Mease, Alice B. Gottlieb, Shelly Kafka, Alexa P. Kollmeier, Elizabeth C. Hsia, Xie L. Xu, May Shawi, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Paraneedharan Ramachandran, Yanli Zhuang & Iain B. McInnes. (2021) Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis. The Journal of Rheumatology 48:12, pages 1815-1823.
Crossref
Crossref
Marta Amigo-Basilio, Covadonga Álvarez-González, Carlos Cobo-Vázquez, Isabel Leco-Berrocal, Luis Miguel Sáez-Alcaide & Cristina Méniz-García. (2021) Management of Patients under Treatment with Monoclonal Antibodies and New Biological Therapies. Applied Sciences 11:11, pages 4865.
Crossref
Crossref
A. Blauvelt, C. Paul, P. Kerkhof, R.B. Warren, A.B. Gottlieb, R.G. Langley, F. Brock, C. Arendt, M. Boehnlein, M. Lebwohl & K. Reich. (2020) Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies. British Journal of Dermatology 184:4, pages 640-651.
Crossref
Crossref
Atul Deodhar, Philip S Helliwell, Wolf-Henning Boehncke, Alexa P Kollmeier, Elizabeth C Hsia, Ramanand A Subramanian, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Yanli Zhuang & Christopher T Ritchlin. (2020) Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. The Lancet 395:10230, pages 1115-1125.
Crossref
Crossref
K. BRAZDILOVA, T. KOLLER, Z. KILLINGER & J. PAYER. (2019) Prevalence and Risk Factors for Drug-Induced Liver Injury Among Patients With Rheumatic Diseases Treated With Biological Therapy: A Single-Center Experience. Physiological Research, pages S157-S163.
Crossref
Crossref
Mayara Costa de Camargo, Bruna Cipriano Almeida Barros, Izabela Fulone, Marcus Tolentino Silva, Miriam Sanches do Nascimento Silveira, Iara Alves de Camargo, Silvio Barberato-Filho, Fernando de Sá Del Fiol & Luciane Cruz Lopes. (2019) Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting. Frontiers in Pharmacology 10.
Crossref
Crossref
Anca Raducan, Stefana Bucur, Constantin Caruntu, Traian Constantin, Iuliana Nita, Nicuta Manolache & Maria-Magdalena Constantin. (2019) Therapeutic management with biological anti-TNF-α agent in severe psoriasis associated with chronic hepatitis B: A case report. Experimental and Therapeutic Medicine.
Crossref
Crossref
J.L. López-Estebaranz, P. de la Cueva-Dobao, C. de la Torre Fraga, M. Galán Gutiérrez, E. González Guerra, J. Mollet Sánchez & I. Belinchón Romero. (2018) Management of Moderate to Severe Psoriasis in Routine Clinical Practice in Spanish Hospitals. Actas Dermo-Sifiliográficas (English Edition) 109:7, pages 631-642.
Crossref
Crossref
J.L. López-Estebaranz, P. de la Cueva-Dobao, C. de la Torre Fraga, M. Galán Gutiérrez, E. González Guerra, J. Mollet Sánchez & I. Belinchón Romero. (2018) Manejo de la psoriasis moderada-grave en condiciones de práctica habitual en el ámbito hospitalario español. Actas Dermo-Sifiliográficas 109:7, pages 631-642.
Crossref
Crossref
Tzu-Hao Li, Hsien-Tzung Liao, Yi-Fan Huang, Yu-Chuan Shen, Yao-Chang Chiu, Wei-Sheng Chen, Ming-Han Chen, Chang-Youh Tsai & Deh-Ming Chang. (2018) The current status and unmet needs in the management of psoriatic arthritis: Viewpoint from physicians in Taiwan. Journal of the Formosan Medical Association 117:5, pages 404-412.
Crossref
Crossref
Arthur Kavanaugh, M. Elaine Husni, Diane D. Harrison, Lilianne Kim, Kim Hung Lo, Jocelyn H. Leu & Elizabeth C. Hsia. (2017) Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis. Arthritis & Rheumatology 69:11, pages 2151-2161.
Crossref
Crossref
Mark Corbett, Fadi Chehadah, Mousumi Biswas, Thirimon Moe-Byrne, Stephen Palmer, Marta Soares, Matthew Walton, Melissa Harden, Pauline Ho, Nerys Woolacott & Laura Bojke. (2017) Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation. Health Technology Assessment 21:56, pages 1-326.
Crossref
Crossref
L. Puig. (2017) Registries and biologics: disease populations matter. British Journal of Dermatology 176:3, pages 567-568.
Crossref
Crossref
A. Alani, K. Ahmad, M. Sadlier & B. Ramsay. (2016) Malignancy while on biologics in the treatment of psoriasis. A Case series. Journal of the European Academy of Dermatology and Venereology 30:4, pages 693-695.
Crossref
Crossref
A.B. KimballJ. SchenfeldN.A. AccorttM.S. AnthonyK.J. RothmanD. Pariser. (2015) Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States. British Journal of Dermatology 173:5, pages 1183-1190.
Crossref
Crossref
Lida Radfar, Roshanak E. Ahmadabadi, Farah Masood & R. Hal Scofield. (2015) Biological therapy and dentistry: a review paper. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 120:5, pages 594-601.
Crossref
Crossref
Keng-Yi Wu, Deng-Ho Yang & Chun-Wen Chen. (2015) Pyogenic Baker cyst in a patient with psoriatic arthritis during etanercept therapy. Annals of Saudi Medicine 35:3, pages 260-262.
Crossref
Crossref
M Burlando, E Cozzani, C Chinazzo, M larosa, M Boggio & A Parodi. (2015) Bilateral Warthin tumor in psoriatic patients in therapy with multiple immunosuppressive therapy. International Journal of Immunopathology and Pharmacology 28:1, pages 138-141.
Crossref
Crossref
Luciane Cruz Lopes, Miriam Sanches do Nascimento Silveira, Iara Alves de Camargo, Silvio Barberato-Filho, Fernando de Sá Del Fiol & Claudia Garcia Serpa Osorio-de-Castro. (2014) Biological drugs for the treatment of psoriasis in a public health system. Revista de Saúde Pública 48:4, pages 651-661.
Crossref
Crossref
Juan Guinea-ViniegraMaría JiménezHelia B. SchonthalerRaquel NavarroYolanda DelgadoMaría José Concha-GarzónErwin TschachlerSusanna ObadEsteban DaudénErwin F. Wagner. (2014)
Targeting
miR-21
to Treat Psoriasis
. Science Translational Medicine 6:225.
Crossref
Crossref
Roberta Ramonda, Carlo Foresta, Augusta Ortolan, Alessandro Bertoldo, Francesca Oliviero, Mariagrazia Lorenzin, Damiano Pizzol, Leonardo Punzi & Andrea Garolla. (2014) Influence of tumor necrosis factor α inhibitors on testicular function and semen in spondyloarthritis patients. Fertility and Sterility 101:2, pages 359-365.
Crossref
Crossref
Robert Eisenberg. 2014. Stiehm's Immune Deficiencies. Stiehm's Immune Deficiencies
889
906
.
Lara Wine-Lee, Sara C. Keller, Marissa B. Wilck, Stephen J. Gluckman & Abby S. Van Voorhees. (2013) From the Medical Board of the National Psoriasis Foundation: Vaccination in adult patients on systemic therapy for psoriasis. Journal of the American Academy of Dermatology 69:6, pages 1003-1013.
Crossref
Crossref
L. Puig, J.M. Carrascosa, G. Carretero, P. de la Cueva, R.F. Lafuente-Urrez, I. Belinchón, M. Sánchez-Regaña, M. García-Bustínduy, M. Ribera, M. Alsina, C. Ferrándiz, E. Fonseca, V. García-Patos, E. Herrera, J.L. López-Estebaranz, S.E. Marrón, J.C. Moreno, J. Notario, R. Rivera, C. Rodriguez-Cerdeira, A. Romero, R. Ruiz-Villaverde, R. Taberner & D. Vidal. (2013) Spanish Evidence-Based Guidelines on the Treatment of Psoriasis With Biologic Agents, 2013. Part 1: On Efficacy and Choice of Treatment. Actas Dermo-Sifiliográficas (English Edition) 104:8, pages 694-709.
Crossref
Crossref
L. Puig, J.M. Carrascosa, G. Carretero, P. de la Cueva, R.F. Lafuente-Urrez, I. Belinchón, M. Sánchez-Regaña, M. García-Bustínduy, M. Ribera, M. Alsina, C. Ferrándiz, E. Fonseca, V. García-Patos, E. Herrera, J.L. López Estebaranz, S.E. Marrón, J.C. Moreno, J. Notario, R. Rivera, C. Rodriguez-Cerdeira, A. Romero, R. Ruiz-Villaverde, R. Taberner & D. Vidal. (2013) Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis con agentes biológicos, 2013. I. Consideraciones de eficacia y selección del tratamiento. Actas Dermo-Sifiliográficas 104:8, pages 694-709.
Crossref
Crossref
M. Esposito, P. Gisondi, N. Cassano, G. Ferrucci, M. Del Giglio, F. Loconsole, A. Giunta, G.A. Vena, S. Chimenti & G. Girolomoni. (2013) Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study. British Journal of Dermatology 169:3, pages 666-672.
Crossref
Crossref
L. Puig, P. de la Cueva, M. Linares, J. Suarez, M. Velasco, D. Vidal, A. Zulaica & C. García-Calvo. (2013) Expert Report on Psoriasis: Spanish Dermatologists’ Opinions on the Use of Biologic Agents to Manage Moderate to Severe Psoriasis in Adults. Actas Dermo-Sifiliográficas (English Edition) 104:5, pages 400-408.
Crossref
Crossref
L. Puig, P. de la Cueva, M. Linares, J. Suarez, M. Velasco, D. Vidal, A. Zulaica & C. García-Calvo. (2013) Informe de expertos en psoriasis: opinión de los dermatólogos españoles sobre el manejo de la psoriasis moderada-grave con agentes biológicos en pacientes adultos. Actas Dermo-Sifiliográficas 104:5, pages 400-408.
Crossref
Crossref
Jonathan Shintaku & Denis C. Guttridge. (2013) Reining in nuclear factor-kappaB in skeletal muscle disorders. Current Opinion in Clinical Nutrition and Metabolic Care 16:3, pages 251-257.
Crossref
Crossref
Shigaku Ikeda, Hidetoshi Takahashi, Yasushi Suga, Hikaru Eto, Takafumi Etoh, Keiko Okuma, Kazuo Takahashi, Takeshi Kanbara, Mariko Seishima, Akimichi Morita, Yasutomo Imai & Takuro Kanekura. (2013) Therapeutic depletion of myeloid lineage leukocytes in patients with generalized pustular psoriasis indicates a major role for neutrophils in the immunopathogenesis of psoriasis. Journal of the American Academy of Dermatology 68:4, pages 609-617.
Crossref
Crossref
Adrian Reuben. 2013. Drug-Induced Liver Disease. Drug-Induced Liver Disease
569
591
.
Ilse Hoffman, Tania Claeys, Séverine Vermeire, Gert Van Assche, Peter Witters & Paul Rutgeerts. 2013. Pediatric Inflammatory Bowel Disease. Pediatric Inflammatory Bowel Disease
345
355
.
Raquel Cuchacovich, Rodolfo Perez-Alamino, Ignacio Garcia-Valladares & Luis R. Espinoza. (2012) Steps in the management of psoriatic arthritis: a guide for clinicians. Therapeutic Advances in Chronic Disease 3:6, pages 259-269.
Crossref
Crossref